OZONE WORLD LIMITED

Standalone (Ss. in Less									
Particulars	Quarter ended	Quarter ended	9 Months ended	9 Months ended					
	31-12-2021	31-12-2020	31-12-2021	31-12-2020					
	Unaudited	Unaudited	Unaudited	Unaudited					
Total Income from operations	0.00	30.19	33.94	64.41					
Not Profit / (Loss) from ordinary activities after tax	(7.25)	18.82	9.08	34.76					
Total Comprehensive income for the period (Comprising profit for the period and Other Comprehensive Income for the period) after tax	(7.25)	18.82	9.08	34.76					
Equity Share Capital	369.91	369.91	369.91	369,91					
Earnings Per Share (of Rs. 10/- each)		74-16							
Basic :	(0.20)	0.51	0.25	0.94					
Diluted :	(0.20)	0.51	0.25	0.94					

₱ SATYA MicroCapital Ltd. SATYA MicroCapital Limited

(CIN: U74899DL1995PLC068688)

Registered Office Address: 519, 5th Floor, DLF Prime Towers, Okhla Industrial Area, Phase - I, New Delhi-110020, India, Phone No. 011- 49724000, website: www.satyamicrocapital.com

EXTRACT OF THE UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2021

S. No.	Particulars	Quarter Ended December 31, 2021	Year Ended March 31, 2021
		Unaudited	Audited
1	Total Income from operations	1,056.24	2,672.18
2	Net: Profit for the period (before Tax, Exceptional and/or Extraordinary items)	51.64	151.06
3	Not Profit for the period before tax (after Exceptional and/or Extraordinary items)	51.64	151.06
4	Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	39.76	102.17
5	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	39.39	101.88
6	Paid up Equity Share Capital	460.01	458.50
7	Reserves (excluding Revaluation Reserve)	250.96	118.83
8	Securities Premium Account	3,475,41	3,466,96
9	Net worth	4,186,38	4.044.29
	Paid up Debt Capital/ Outstanding Debt	17,783.18	11,278.76
11	Outstanding Redeemable Preference Shares	NI	Nil
12	Debt Equity Ratio (no. of times)	4.25	2.79
13	Earnings Per Share (of Rs.101- each) (for continuing and discontinued operations) (Rs.) 1. Basic (EPS)*:	0.87	2.57
	2. Diluted (DPS)*:	0.86	2.53
14	Capital Redemption Reserve	NI	NEI
15	Debenture Redemption Reserve	NI	Nil
	Debt Service Coverage Ratio	NA.	NA.
17	Interest Service Coverage Ratio	1.11	1.12

The unsuffied standalone financial results for the quarter and nine months ended Docember 31,2021 have been reviewed by the Audit Committee and threather approved and tabken on record by the Bloard of Directors at their meetings held on February 12, 2022. The unaudited standalone financial results was also limited reviewed by the statulory auditors of the Company.

The above is an extract of the detailed format of unaudited standalone financial results for the quarter and rime months ended Bocember 31,2021 field with the Stock Exchanges under Regulation \$2 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited weaking of the SEBI (Listing Collegations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited standalone financial command on the velocities of the SEBI (Listing Obligations and Disclosure Requirements). The settlement of the standalone of th

This sottact of unaudited standardore financial results for the quarter and nine months ended December 31,2 has been prepared in accordance with the requirement of Regulation 52 of the SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015, read with circular no. SEBI/HO/IDDHSCIR/2021/0000000 dated October 5, 2021.

Disclosure Requirements) Regulations, 2010, reac with unusual in the default October 5, 2021.

The Company has availed relaxation provided by SEBI vide its circular no SEBIHODDHSICIR20210000000637.

The Company has availed relaxation provided by SEBI vide its circular no SEBIHODDHSICIR20210000000637.

The Company has availed relaxation provided by SEBI vide its circular no SEBIHODDHSICIR20210000000637.

The Company has availed relaxation he column for the corresponding quarter ended December 31, 2020.

The Company has availed relaxation he column for the corresponding quarter ended December 31, 2021.

For and on helafied of the Board of Directors of For and on helafied of the Board of Directors of SATYA MICROCAPITAL LIMITED.

Self-

Sd/-Vivek Tiwari Managing Director, CEO & CIO Place : New Delhi Date: February 12, 2022

adani

ADANI WILMAR LIMITED

Registered Office: "Fortune House", Nr Nevrangpura Railway Crossing, Navrangpura, Ahmedabad - 380 009. CIN: U151460J1999PLC035320
Phone: 079-26455650; Fax: 079-26455621; Email: Investor:relations@adaniwilmar.in

				(7 in Crore
Sr. No.	Particulars	Quarter ended December 31, 2021	Nine months ended December 31, 2021	Quarter ended December 31, 2020
		(Unaudited)	(Unaudited)	(Unaudited)
1	Revenue from Operations	14,378.66	39,253.18	10,229.49
2	Net Profit for the period before taxes and Share in profit/(loss) of Joint Ventures (before Exceptional and/or Extraordinary items)	306.29	760.48	171.33
3	Net Profit for the period before taxes and before Share in profit/(loss) of Joint Ventures (after Exceptional and/or Extraordinary Items)	306.29	760.48	171.33
4	Net Profit for the period after taxes and before Share in profit/(loss) of Joint Ventures (after Exceptional and/or Extraordinary items)	220.52	555.12	110.02
5	Net Profit for the period after taxes and after Share in profit/(loss) of Joint Ventures (after Exceptional and/or Extraordinary items)	211.41	569.45	127.39
6	Total Comprehensive Income for the period [Comprising of Profit for the period (after tax) and other Comprehensive Income (after tax)]	209.69	563.87	127.10
7	Paid-Up Equity Share Capital (Face Value of ₹1 Each)	114.29	114.29	114.29
8	Earnings Per Share (Face Value of ₹1 Each) Basic and Diluted (in ₹) (Not Annualised)	1.85	4.98	1.11

The aforesaid results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 14, 2022.
The Statutory Auditors have careful out limited review of consolidated financial results of the Company for the quarter and finie months ended on December 91, 2021.
Additional information on Standatone Plannical Revuelts is as follows:

(f. in Cross)

m December 31, 2021.

Quarter sinded December 31, 2021 (f in Cores)

Quarter sinded December 31, 2021 (Junudited)

13,763.47 38,087.75 10,229.49

240.66 584.85 111,02

Think above is an extract of the detailed format of the Standalone and Consolidated Financial Results for the quarter and nine menths ended on December 31, 2021 filed with the Stockhanges under Regulation 33 of the SEBI (Listing Obligations and Discissivar Requirements, Regulations, 2015. The full format of the Standalone and Consolidated Financial Results for the quarter and nine months ended on December 31, 2021 are evalible on the Section Section (Section Regulations) and Company's website wave advantaged to the control of the section of

Place: Ahmedabad Date: February 14, 2022

Angshu Mallick Managing Director and Chief Executive Officer

Crompton

PUBLIC NOTICE

wast somes sed mobile number as jer the following procedure. Contract Compeny? Register and Shere Transfer Agent, Kife Technologies Private Luristed, by sending an enset at instructions of the Merchae, coarned copy of their security of the contract state, following, and the second of the second copy of their second copy of tepository participants.

Som Shareholders whose email address and mobile number

Alembic

ALEMBIC LIMITED

CIN: L25100GJ1967PLC000033 Regd.Office: Alembic Road, Vadodara 390 603 Tel: 0265-2280550 Website: www.siembiclimited.com Email: alembic investors@slembic.co.in

Extract of Statement of Consolidated Unaudited Financial Results for the Quarter and Nine Months ended 31" December, 2021

		(₹ in Lacs e	xcept per share data)			
·	Consolidated					
	Quarter Ended	Quarter Ended	Nine Months Ender			
Particulars	31.12.2021	31.12.2020	31.12.2021			
	Unaudited	Unaudited	Unaudited			
Total Income from Operations	2,106	1,750	14,476			
Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	430	580	9,204			
Net Profit for the period before Tax (after Exceptional and/or Extraordinary items)	430	580	9,204			
Net Profit for the period after Tax (after Exceptional and/or Extraordinary items)	412	487	8,154			
Total Comprehensive Income for the period	12,625	7,575	31,937			
Equity Share Capital	5,136	5,135	5,136			
Earning Per Share (of ₹ 2/- each) Basic & Diluted	2.02	3.33	8.61			
Note 1. Standalone detalls:						
Particulars	Quarter Ended	Quarter Ended	Nine Months Ended			
1 81903813	31.12.2021	31.12.2020	31.12.2021			
1	Unaudited	Unaudited	Unavelled			

The above is an extract of the detailed format of financial results flied with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Regulations) (Regulations, 2015. The full format of the financial results are available on the Company's website at www.aiembiclimited.com and on Stock Exchange's website at www.nsendit.com and www.bscindis.com

14,334

PUBLIC NOTICE

જા. સ્વેક્ષિણ ૧૩ મહિન્દ્રાં બેંક (લિપ્સિટ) અમાન Antak.co જા. સ્વેક્ષિણ ૧૩ મહિના, ૧૭ મહિન, ૧૭ મહિન, ૧૯ મહિના, ૧૯ મહિ

એપીએસી	Midi	ઉદ્યારકર્તાનું નામ	ยาจ	580	tilei	સોસ વ સામ
1025353	28134	અબ્દુલસમદ એન. શેખ	ay.	બરોડા	અંકલેશ્વર	24.
1400220	W4303	ઉંક્રકદભાઈ અમધાભાઈ વસાવા	ajv.	બરોડા	અંકલેશ્વર	39.
1442408	911/23	ઉંકકદભાઈ અમધાભાઈ વસાવા	ગુજ.	બરોડા	sischts	24.
1000470	92390	ઉંક્રક્ટભાઈ અમધાભાઈ વસાવા	ay.	બરોડા	અંકલેશ્વર	40.
2013414	118848	ખેર નિલેશભાઈ જગદીશભાઈ	ગુજ.	રાજકોટ	(अडितेल गर	10.
1410010	20822	અર્પણ ક્રાંતિલાલ જોપી	3Y.	બરોડા	ભરૂપ કેર્સ	WO.
1/11/01	4034	અર્પણ ક્રાંતિલાલ જોપી	ગુજ.	બરોડા	ભરૂપકેસી	Yw.
4058500	123514	મુષ્ટકાર એવુબ પટેલ	3JY.	બરોડા	ભરૂચકેસી	19.
5002845	115/08	રતનબેન મહેશભાઈ કોળી	gy.	બરોડા	ભરૂચ કેર્સી	50.
1020182	109240	સોની પ્રિકલ કલ્પેશભાઈ	ગુજ.	બરોડા	ભરૂપકેર્શ	39.
5058502	123440	ભલોદીમા સાગર	ay.	બરોડા	બીપીસી શેક	W3.
SOROORS	110002	થાવડા રૂપાભાઈ ગોસભાઈ	ગુજ.	शुक्त	5dl2PIPI	37.
1922008	naccs	ગો. મુસ્તકીય મો. કાસીંગ ફાદીવાલા	ગુજ.	भुक्त	5disHPi	39.
1010588	110128	નવાપરા તુપલ લાલુભાઈ	ગુજ.	सुरत	\$dis2lbi	90.
1430151	42208	આદીશ પરેશભાઈ પહેલ	3Y.	भुक्त	होरह कर्वस	420.
4884800	4500A	રાયચા યશભાઈ જવંતિભાઈ	ગુજ.	зірізки	મહિલ્લગર	34.
2020020	114305	30ગીયા આપેશ પંચાલ	ay.	зірізки	મકેસાણા	94.
1431505	42040	પંચાલ પ્રતિક રાજેશભાઈ	ayv.	зірізки	મહેરાણા	¥1.
1941068	42010	પટેલ પંકપકુષાર બચુભાઈ	gy.	зірізки	મહેરાણા	¥02.
1644830	23381	પટેલ પંક્રજકુગાર બચુભાઈ	agv.	зірізки	મહેરાણા	492.
1434863	64464	પદાણ સાત્રેનાબીબી યુસુફબાન	gy.	зірізки	મફેશણા	84.
1488308	158343	સંજયભાઈમાંતિભાઈરાઇડીયા	34.	રાજકોટ	મોરબી	109.
1555564	53595	દિપક્રુષાર ગિરધરભાલ મેવાડા	34.	зірізки	भावनपुर	¥9.
1058853	111004	जिल्ह्यामार्थ सीटीलार्ध सेमा -	34.	शक्षांट	રેસકોર્સ	39.
3053354	143586	બિજલભાઈ શીદીભાઈ છેયા	34.	शक्षकोट	રેસકોર્સ	80.
1000048	2040c	સાલીબએફગદ ફારૂકએફગદ સેવદ	34.	зірізин	કોરેલાઈટ	¥0.
1664363	244e3	કંદોઈ નીતુબેન એન.	ગુજ.	બરોડા	तरशाजी	18.
JARCSSA.	¥330¥	રાજુભાઈથી. ખટીક	ay.	બરોડા	पडशाली	29.
1093110	106544	ભરતભાઈ ગોબરભાઈ બાબરીયા	34.	श्रुक्त	વસભારોક	110.
1653837	103934	धर्मेन्द्रलार्डंदुवालार्डंबुवडीया	34.	सुरत	वशका शेड	141
1440000	68050	દાર્મેશભાઈ દિલીપભાઈ સુબા	37.	भुश्त	વસભારોક	49.
1558515	93980	દિનેશભાઈ ભીખાભાઈ મેંદાપરા	34.	भुश्य	વરાછા રોક	189.
5057590	119810	કલ્પેશ કાનજીભાઈ વડોદરીયા	34.	शुक्त	વરાછા શેક	114
1403999	ccsan	કાપડીયા દિપેશ મનુભાઈ	gy.	शुक्त	વરાછા રોક	93.
JC8358A	101013	ગતિપકુગાર	gy.	शुक्त	વરાછા રોક	81.
1444003	02490	રાંતાઆદ્યાનું મુક્કાલાદ ભટારા	34.	शुक्त	વશભા શેક	18.

ઉપરોક્ત જણાવેલ સોનાના દાગીનાની જાફેર ફરાજી **કોટક મફિન્દ્રા બેંક લિમિટેકની સં** શામાંઓ આવે તા. ૨૪, ૦૨, ૨૦૨૨ ના રોજ સ્વાર્થ રે. ૧૦, ૩૦ વાળ્યે ચોળાવો. ઉત્પાદન હાજુએ લગ તેમ ઇંચુલ ડેક મેલીકાંડો તેફીએ લક્કો પુત્ર, માટે તેમ જ સ્કામના પ્રાથમિત નકતો તેને મોરીજના સાથે કે હોડામ સર્કિલા દરકરોને સ્ટક્કાને સ્ટિક્સ મેલે તાલ્યાન રહેતે. એક કંદને પાત્ર કોઈ જાતની સુધાન લાખા વગર સ્ટક્સું તેમા, તાર્કિત, સ્ત્રમ ને બદાવલ આવેલા ટેક રહેતા એક લિંગ પાત્ર કોઈ 5. મોરીજ સ્કામના લાખા વગર સ્ટક્સું તેમા, તાર્કિત, સ્ત્રમ ને બદાવલ આવેલા ટેક રહેતા એક લિંગ લીકાર્ટિક મોરી સ્ટાલ



Date: 14" February, 2022

EQUITAS HOLDINGS LIMITED

Regd. Office: 410A, 4th Floor, Spencer Plaza, Phase II, No.769, Mount Road, Anna Salai, Chennai CIN: L65100TN2007PLC064069 | Ph: 044 4299 5000 | www.equitas.in

Statement of Standalone & Consolidated Unaudited Financial Results for the Three Months and Nine months period Ended 31 December 2021

			Stand	alone		Consolidated			
SI. No.	Particulars	Three Morths Ended Dec 31, 2021	Three Months Ended Dec 31, 2020	Nine Months Ended Dec 31, 2021	Year Ended Mar 31, 2021	Three Months Ended Dec 31, 2021	Three Months Ended Dec 31, 2020	Nine Months Ended Dec 31, 2021	Year Ended Mar 31, 2021
		Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited
1 2	Total Income from Operations Net Profit for the Period / Year Before Tax,	494.86	16,260.35	1,469.72	17,772.88	104,374.94	115,243.52	299,171.51	382,069.13
3	Exceptional and / or Extraordinary items Net Profit for the Period / Year Before Tax	(200.91)	16,145.57	511.31	16,944.11	13,037.21	30,806.51	20,716.28	65,609.21
	after Exceptional and / or Extraordinary items	(6,320.07)	16,145.57	(5,607.85)	16,944.11	6,918.05	30,806.51	14,597.12	65,609.21
4	Net Profit for the Period / Year After Tax after Exceptional and / or Extraordinary items	(6,275.70)	14,231.89	(5,755.94)	14,695.12	3,514.01	25,145.11	9,277.59	51,379.53
5	Total Comprehensive Income for the Period / Year [(comprising profit / (loss) for the period (after		0.000.000.00		70.000.000		200000000000000000000000000000000000000	10000000000	
	tax) and other comprehensive income (after tax)]	(6,276.82)	14,231.93	(5,759.31)	14,695.60	3,385.22	26,170.80	8,930.91	51,779.62
6 7	Equity Share Capital Other Equity	34,179.01	34,179.01	34,179.01	34,179.01 144,199.00	34,179.01	34,179.01	34,179.01	34,179.01 273,448.39
8	Earnings Per Share (EPS) for Continuing and discontinued Operations, (not annualised)				(5)				238
(i)		(1.84)		(1.68)	4.30		7.36		15.03
(ii)	Diluted (₹)	(1.84)	4.16	(1.68)	4.30	1.03	7.36	2.71	15.03

Executive Director and CEO

ATUL AUTO LIMITED

Reg. Office: Survey No. 86, Plot No. 1 to 4, 8-8, National Highway, Near Microwave Tower, Shapar (Veraval),
Dist. Rajkot, Gujarat 360 024 CIN L54100G/1986PLC016999 1 Website: www.atulauto.co.in 1 E-Mail: info@atulauto.co.in



STANDALON CONSOLIDATED 31.12.2021 31.12.2020 (Unaudited) 31.12.2021 (Unaudited 31.12.2021 31.12.2020 31.12.2021 Total income from Operation (Net) 20,796 10,284 22,058 10,171 Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extra ordinary Items) (1.134)137 (2.549)(1.156)131 (2.593) Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extra ordinary Items) (1,134)137 (2,549)(1,156)131 (2,593) Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extra ordinary Items) (852) (1,920) (881) 100 (1,975) (846) 99 (1.910) (874) 118 (1,927) Total Comprehensive Income for the period [Comprising Profit/(joss for the period (after tax) and Other Comprehensive Income (after tax)] Paid up Equity Share Capital Earning Per Share (Basic and Diluted but not annualised) (Face value of Rs. 5/-) (3.88)0.47 (8.75) (4.02)0.57 (8.76)

For and on behalf of Board of Directors of Atul Auto Limited



Date : February 12, 2022 Place : Shapar (Dist. Rajkot)

wilmar

ADANI WILMAR LIMITED

Registered Office: "Fortune House", Nr Navrangpura Railway Crossing, Navrangpura Ahmedabad - 380 009, CIN : U151466.11999PL.003520. Phone: 079-26455601, Paic 079-26455601, Emil. Investocrelations@adeniwlimar.let

Extract of Unaudited Consolidated Financial Results for the Quarter and Nine months ended December 31, 2021

Sr. No.	Particulars	Quarter ended December 31, 2021	Nine months ended December 31, 2021	Quarter ended December 31, 2020
0.00		(Unaudited)	(Unaudited)	(Unaudited)
1	Revenue from Operations	14,378.66	39,253.18	10,229.49
2	Net Profit for the period before taxes and Share in profit/(loss) of Joint Ventures (before Exceptional and/or Extraordinary items)	306.29	760.48	171.33
3	Net Profit for the period before taxes and before Share in profit/(loss) of Joint Ventures (after Exceptional and/or Extraordinary items)	306.29	760.48	171.33
4	Net Profit for the period efter taxes and before Share in profit/(loss) of Joint Ventures (after Exceptional and/or Extraordinary itams)	220.52	555.12	110.02
5	Net Profit for the period after taxes and after Share in profit/(loss) of Joint Ventures (after Exceptional and/or Extraordinary items)	211,41	569.45	127.39
6	Total Comprehensive income for the period [Comprising of Profit for the period (after tax) and other Comprehensive Income (after tax)]	209.69	563.87	127.10
7	Paid-Up Equity Share Capital (Face Value of £1 Each)	114,29	114.29	114,29
	Earnings Per Share (Face Value of €1 Each) Basic and Diluted (in €) (Not Annualised)	1,85	4.98	1.11

- The aforesaid results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 14, 2022. The Statutory Auditors have carried out limited review of consolidated financial results of the Company for the quarter and nine months ended on December 31, 2021.

3 /	Additional information on Standalone Financial Results is as follows:							
Sr. No.	Particulars	Quarter ended December 31, 2021	ended ended December December					
		(Unaudited)	(Unaudited)	(Unaudited)				
	Revenue from Operations	13,763.47	38,087.75	10,229.49				
b	Profit Before Tax	322.34	785.32	172.07				
с	Profit After Tax	240.66	584.85	111.02				

The above is an extract of the detailed format of the Standalone and Consolidated Financial Results for the quarter and nine months ended on December 31, 2021 filled with the Stock Exchanges under Regulation 35 of the SEB (Listing Obligations and Disciousure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financial Results for the quarter and nine months ended on December 31, 2021 are available on the Stock Exchange websites (oww.basindis.com) - www.nasindis.com) and Company's website

For and on behalf of the Board of Directors

Angshu Mallick Managing Director and Chief Executive Officer

GUJARAT WATER SUPPLY & SEWERAGE BOARD, GANDHINAGAR

GUJARAT WAIER SUPPLY & SEWERAGE BOARD, GANDHINAGAR Executive Engineer, P.H.W. On., Nashahrana Executive Engineer, P.H.W. On., Nashahrana Executive Engineer, P.H.W. On., Nashahrana P. Garder Holder No. 14. & 6 (27 Alternity Versus 2021-22 Executive Engineer, P.Arlic Health Works Division, Nakhahrana Kutch through e-Individual States in Work. Proxing, Supplying Lowering, Isping And Jainting Various Dis D. B. PVC Pipeline, Constitution of Designing of WIP and Storage at various Variensed Compiles villages, Pumping Machinary For Variensed Compiles FM/SS Augmentation Scheme (Under Nal Se Jai Programme 2000-21 Variensed Compiles (In Mahahrana & Blink (1911 Alternity) Estimated Cost Re. 7.14,58,750.60 (Tender ID No. 506063)

Ferroding, Supplying Lawering, Jesing And Jainting Varieus Dis D. B. PVC Pipeline, Construction Storage at various villages, Pump house and compound will at varieus Head erick, Pumping Machinary and Is year CMM Work For Suthari FM/SS Augmentation Scheme (Under Nal Se Jai Programme 2001-49) Its Addises Mitch Estimated Cost Re. 5,04,43,911.20 (Tender ID No. 506063)

Tanadar can be deveniceded aller D. ti 1000/2022 Last Dista of online Suthanisan in s III 0. 1400/2022 at 11:00 Hours, Further datals are available on the Website beginners 2001 http://doi.org/10.1101/2007.1101.2007.

on the Website http://www.gaschz.ze.te.te.co/poschzie.com/ http://www.gaschpropours.com/ Rantingthe problem of direking water in sural areas, it is requested to, contact the helpine no. 1916/1400 200 1400 of Gujanst Water Supply & Sowerage Board, Gardylmagar. DORKOT-GH-901/2022

Total income from Operations

Net Profit(Loss) for the period (before 16.34 21.19 (181.19) (9.98) 159.83 Tax and Exceptional items)
Net Profit(Loss) for the perio
Tax and after Exceptional items 17.96 10 ON 16 34 159.83 21.19 (181 10) Net Profit(Loss) for the period (after (5.12) 155.36 (187.01) 3.3 Tax and Exceptional iter Total Comprehensive income for the period Profiti(Loss) for the period (After Tax) and 7.21 155.3 (187.01) 3.3 (5.12) other comprehensive income (after Tax) Paid-up Equity share capital (face 950.00 950.0 950.00 950.00 950.00 950.00 value) of Rs. 10Feach share Reserves (excluding Revaluation Reservations in the Balance Sheet of previous year 1.953.3 Earnings Per Share (before and after 0.0 0.08 1.64 (1.97)extraordinary items) (of Rs. 10/- each) Basic and Diluted

Notes:

1. The above result is an extracts of the details unaudited Financial Result for the Quarter and Nine Months ended 31st December, 2021 fliest with the stock exchange under regulation 33 of SSBI (Listing Obligation and Disclosure Requirement) Regulation, 2015. The flull financial result for the Quarter and Nine Months ended on 31" December, 2021 we available on the website of the stock exchange in www.beenda.com and website of the company is were street-havy delation com

For SHREE BHAVYA FABRICS LIMITED ottam R. AGARWAL Managing Directo (DIN: 00396869)

ATUL AUTO LIMITED

Reg. Office: Survey No. 86, Plot No. 1 to 4, 8-8, National Highway, Near Microwave Tower, Shapar (Veraval).
Dist. Raikot. Gujarat 360 024 CIN L54100G/1986PLC016999 | Website: www.atulauto.co.in | E-Mail: info@atulauto.co.in

Place: Ahmedoba Date: 14.02.2022

			STANDALONE		CONSQUENTED			
100		200		Nine Months				
St. No.		Quarte	Quarter Ended		Quarter Ended		Nine Months Ended	
		31.12.2021 (Unaudited)	31.12.2020 (Unaudited)	31.12.2021 (Unaudited)	31.12.2021 (Unaudited)	31.12.2020 (Unaudited)	31,12,2021 (Unaudited	
1	Total income from Operation (Net)	9,377	10,171	20,796	10,284	10,171	22,058	
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extra ordinary Items)	(1,134)	137	(2,549)	(1,156)	131	(2,593)	
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extra ordinary Items)	(1,134)	137	(2,549)	(1,156)	131		
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extra ordinary Items)	(852)	106	(1,920)	(881)	100	6	
5	Total Comprehensive Income for the period [Comprising Profit/(loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(846)	99	(1,910)	(874)	118		
6	Paid up Equity Share Capital	1,097	1,097	1,097	1,097	1,097	1,000	
7	Earning Per Share (Basic and Diluted but not annualised) (Face value of Rs. 5/-)	(3.88)	0.47	(8.75)	(4.02)	0.57	(8.76)	

For and on behalf of Board of Directors of Atul Auto Limited

Jayantibhai J Chandra

ADVERTORIAL

Living with Covid 19



Date: February 14, 2022

Dr Shashank R Joshi MD, DM, FRCP, FICP FACE, FACP Consultant Endocrinologist, Mumbai Member, Maharashtra

COVID-19 Task force Padma Shri Awardee

SARS-CoV-2 is predictably unpredictable but is slow mutating new RNA virus which has clearly disrupted the world since 2020.Gazing into the future of SARS-CoV-2, it is predicted that the new variants of concerns due to mutants would not be eradicated anytime soon but may be less severe, though more contagious like Omicron. The new normal has moved from "herd immunity" (a term which has lost its science as the pandemic evolved) to "endemic word which also needs lots to be thought about.

The evolution of SARS-CoV-2 over the next several months will determine what the end of this global

SARS-CoV-2 to make sig-nificant evolutionary leaps where it may become a manageable condition in most and protecting the most vulnerable likely to deteriorate. We need to live our lives with Covid 19 with care, caution and precautions without fear and panic.

The novel coronavirus disease of 2019 is associated with significant morbidity and mortality. Our current focus is to save every life from covid 19. Most lives are lost in elderly or unvaccinated population or those who have underlying immunocompromised states or co morbid disorders like hypertension, diabetes, heart diseases or kidney or liver issues. The impact of thrombotic complications has been increasingly recognized as an important component of this disease associated with higher risk of death. To add to the burden of thromboembolism, winters are often accompanied with an unusually high occurrence of heart from heart disease, including sudden deaths, tend to increase rapidly at the onset of winters. The risk of having a heart attack during the winter months is twice as high as during the summers. So, people with cardiometabolic conditions must take utmost care to prevent covid 19 or treat aggressively.

The quest for effective drugs to treat COVID-19 and vaccines to prevent complications has been a priority ever since the outbreak of the disease. Up to now, COVID treatment choices have been inferred from the experience with other coronaviruses or viral infection outbreaks. The options currently being used clinically are categorically divided as antivirals, immunomodulators and other drugs. However, it has been observed that the use of such drugs has shown both. limited efficacy & specificity against SAR-COV-2 but evidence continues to be generated. Many of these medicines were repurposed and are still under investigation.



Flu and influenzas pandemics have ravaged the world since 1918 till date. Covid 19 had also seen waves and strains evolve which has seen it evolve from a life-threatening pneumonia like disease from the Wuhan strain till the current less severe Omicron strain which is flu like syndrome in most people now. Omicron related tsunamic like wave is less severe but highly contagious. The manifestations of Omicron are essentially an upper airway disease which is "nose" and "throat" covid. They are fever, nasal congestion/stuffy or blocked nose, sore throat with pain, cough, headache, bodyache, tiredness(fatigue), myalgia (muscle pain) and many others. The lung covid which was seen in the Delta strain can still rarely exist often may have loss of smell and taste should never be missed. Monitoring temperature and oxygen saturation will always be the key in the first week particularly. treatment is the key with antipyretics, anti-inflammatory, antihistamines and simple immunity stimulating micronutrients. So current mild disease can be managed by symptomatic treatment solutions and red flagging the vulnerable groups. Simple medicines like low dose aspirin, statins or anticoagulants save lives in the high risk cardiometabolic co morbidities like diabetes and heart discases.

Symptomatic

vember highlighted the ongotng challenges of life with SARS-CoV-2. The transeach new emerging variant & hence vaccine is only partially effective method of COVID-19.

agents In COVID, vitamin C up to anti-inflammatory and antivirals might be the 1500 mg provides optimum



Rohit Shelatkar harmacy, MSc. Pharmacology Sr. Vice President, Director. Vitabiotics Ltd. UK

Heads the international husiness team along with his participation in the Product Formulations and Regulatory Affairs.

For those who had hoped that 2021 would be the year that put the pandemic in the past tense, it was a harsh reminder that it is still very much present. Rather than laying plans to return to the 'normal' life we knew before the pandemic, 2022 is the year the world must come to terms with the fact that SARS-CoV-2 is here to stay.

The emergence of the Omicron variant last Nooptimal therapy for the disease. The emergence of affordable and powerful oral anti-COVID-19 drugs and the increased uptake of vaccination will bring hope for the end of the COVID-19 pandemic.

Need of the Hour: Boost Immunity

It takes years to develop antiviral drugs & looking at repurposing easilyaccessible which treat COVID symptoms. The need of the that can be taken at home in tablet form to reduce than 100 µg per day. hospital load. Knowledge & detailed science be-hind use of aspirin & promethazine in treating flu like symptoms backed by clinical evidence sufficiently available.

Micronutrient have potential roles in interfering with virus at the entry site, and inhibiting activities of replication cycle of severe acute respiratorysy syndrome coronavirus Micro-nutrient also have immunomodulating, antiinflammatory, antioxidant, and antiviral properties. Therefore, micronutrients mission rate increases with are consequently a promising alterative nutritional approach to combat

in COVID-19.Vitamin B3 not only helps to build and maintain a healthy immune system but it could potentially prevent or reduce COVID-19 symptoms or treat SARS-CoV-2 infection. Ztnc has tmmunomodulatory, antiviral & anti-inflammatory responses and supplementing 15-30 mg Zinc per day in COVID infected is effective. Selenium and Iohour is to look at therapies dine has beneficial effects on immunity, with a dose more

> The COVID-19 pandemtc ts still severe, and most of the drugs currently for COVID-19 are not designed specifically against SARS-CoV-2. The combination of Asptrin, Promethazine and micronutrients inhibits viral proliferation in early stage of COVID-19 thus preventing subsequent severe complications. Clinical evidence suggests that Aspirin, promethazine and micronutrients can shorten the recovery time of COVID-19 symptoms.

Need of the hour with omicron variant is to boost immunity of those vaccinated & unvaccinated